JP Morgan Upgrades Biogen to Overweight, Raises Price Target to $300
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsUpgradesPrice Target
JP Morgan analyst Chris Schott upgrades Biogen (NASDAQ:BIIB) from Neutral to Overweight and raises the price target from $210 to $300.
JP Morgan analyst Chris Schott upgrades Biogen (NASDAQ:BIIB) from Neutral to Overweight and raises the price target from $210 to $300.